Skip to main content

Treatment Clinical Trials for Myelodysplastic Syndrome

Review the myelodysplastic syndrome treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 217

Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome/Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Haploidentical Stem Cell Transplant with Umbilical Cord Blood Transplant for the Treatment of Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Eltrombopag for the Treatment of Relapsed or Refractory Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-0 with TET2 Mutations
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Cladribine, Cytarabine, and Decitabine With or Without Venetoclax and Gilteritinib in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Enasidenib and Azacitidine in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Hyperbaric Oxygen Therapy to Improve Engraftment Following Umbilical Cord Blood Stem Cell Transplantation in Patients with Blood and Lymph Node Cancer
Status: Active
Location: University of Rochester, Rochester, New York
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Decitabine and Cedazuridine for the Improvement of Outcomes in Myelodysplastic Syndrome Patients with Measurable Residual Disease after Donor Stem Cell Transplantation
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Venetoclax for Maintenance Treatment in Patients with AML and MDS After Donor Stem Cell Transplant
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York